6 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
of SGLT2 inhibitors ... DECLARE-TIMI 58 - Dapagliflozin ... DAPA-CKD - Dapagliflozin ... DAPA-HF - Dapagliflozin ... #table #CVD #CKD
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
-2 inhibitors - ... Canagliflozin ( ... Invokana) - Dapagliflozin ... (Steglatro) #diabetes ... #Inhibitors #pharmacology
Indications for and pharmacological properties of approved SGLT2 inhibitors

Canagliflozin - Dapagliflozin - Empagliflozin - Ertugliflozin

#SGLT2 #Inhibitors
inhibitors Canagliflozin ... - Dapagliflozin ... - Empagliflozin ... #Inhibitors #pharmacology ... #table
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors ... - Pharmacology ... the three • Dapagliflozin ... • Euglycemic diabetic ... #Inhibitors #Pharmacology
Summary of Diuretic Agents 
Subclass, Drug, Mechanism of Action, Effects, Clinical Applications, Pharmacokinetics, Toxicities, Interaction
CARBONIC ANHYDRASE
Acetazolamide, others SGLT2 ... Canagliflozin ... • Dapagliflozin, ... #Medications #Pharmacology ... #summary #table
SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the
SGLT2 inhibitors ... SGLT2 inhibitors ... treatment of type II diabetes ... (Invokana®), dapagliflozin ... , #dapagliflozin